TX-FLUENCE
11.8.2022 14:32:09 CEST | Business Wire | Press release
Fluence Bioengineering, Inc. (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, in collaboration with REMY, a horticultural lighting provider to Israel’s growing agriculture industry, is supporting the record introduction of lighting technology solutions to Israel’s medical cannabis facilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220811005211/en/
Israel—considered a world leader in cannabis research, cultivation and advanced regulation—has positioned itself at the forefront of the $74 trillion global cannabis market through highly innovative technology and data applications. The country now boasts supply capabilities that surpass its domestic demand. As the Israeli market matures, more and more indoor farms are capitalizing on leading controlled environment agriculture strategies proven to optimize plant growth and profits.
REMY’s expertise, paired with Fluence’s products and evidence-based best practices for optimal lighting strategies at each phase of cannabis growth, has placed the companies’ collaborative designs in the three core categories of medical cannabis facilities in Israel: greenhouse, indoor and vertical farms.
Hybrid cultivation at Green Fields
Green Fields, which operates the largest medical cannabis growing facility in Israel, features a hybrid greenhouse model of harnessing sunlight and supplementing with artificial lighting to optimize plant quality. The forward-looking company chose Fluence and REMY to install a high-intensity lighting system.
"After working on several projects with REMY, we know the value of their professionalism, expertise and service. That's why we chose them for our flagship project," explained Jonathan Pisso, chief procurement officer of Green Fields. "The difference we saw in the first crop cycle using Fluence lighting was phenomenal. As a result of the facility's control system, we have a great deal of flexibility and maximum control. We have integrated all the technologies with an extremely powerful lighting system, which results in uniform growth and excellent results."
Growing indoors with Springs Valley Cannabis
Another popular type of cannabis facility in Israel is the fully indoor model, which allows control of all crop conditions to ensure uniform growth throughout the year while maximizing quality. Springs Valley Cannabis is setting up to become a major cannabis cultivator in Israel. It elected to use Fluence and REMY for lighting solutions in its indoor facility that covers an impressive 5,000 square meters of canopy.
"When we designed our unique facility, we sought trustworthy partners who would ensure our product would be a market leader. We found it in the combination of Fluence and REMY," said Yossi Shitrit, founder of Springs Valley Cannabis.
Trichome’s urban vertical farm
Located in the heart of an urban industrial area, Trichome operates a fully indoor, multi-tier vertical farming facility. Harnessing the power and control of indoor cultivation methods, Trichome searched for industry-leading partners with experience optimizing environmental parameters in a multi-tier environment. With Fluence’s SPYDR Series, Trichome leverages a high intensity, broad-spectrum strategy that delivers precise and uniform light to the plant canopy.
"Fluence’s and REMY's teams are extremely professional. They are dedicated to our success and bring us added value. The results are already exceeding our initial expectations," said Tony Levi, founder and CEO at Trichome. "It shows the potential for indoor growth in urban centers. The facility utilizes every square meter of the building for efficiency and uniformity."
"Israel is a technological 'playground' for the cannabis market, which makes it easy to examine and adopt advanced technologies quickly," said Timo Bongartz, general manager for Europe, the Middle East and Africa (EMEA) at Fluence. "With the early-adapter frame of mind that the Israeli industry practices, Fluence has managed to deliver expert horticulture knowledge and, together with REMY, cooperate with leading innovative growers to advance their operations."
In addition to providing lighting solutions, REMY specializes in the planning, installation, integration and quality assurance of large-scale agronomic solutions, as well as after-sales service and support.
"At the end of the day, the plant is the best indication for our success or failure—and we are achieving success in multiple, diverse cultivation environments," said Elad Toby, founder, CTO and chief business development officer for REMY.
To learn more about REMY, click here . To learn more about Fluence’s portfolio of luminaires and lighting controls, visit the company’s website here .
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science .
About REMY
Established in 2008, REMY 108 LTD specializes in the planning, installation, integration and quality assurance of large-scale agronomic lighting solutions, as well as after-sales service and support, for commercial crop and food cultivation in Israel and beyond. REMY has been providing its customers with agronomic lighting since 2011 and it has been the company’s main focus since 2018. An authorized reseller of Fluence LED lighting solutions, it today also provides agronomic lighting training at its headquarters in Yanuv. For more information about REMY, visit https://www.remy.co.il/en/grow.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220811005211/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom